LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: Incidence and determinants of venous thromboembolism over 90 days in hospitalized and nonhospitalized patients with COVID-19.

Tholin, Birgitte / Ghanima, Waleed / Selle, Maria Lie / Stavem, Knut

2023 Volume 294, Issue 6, Page(s) 721–729

Abstract: Introduction: COVID-19 is associated with an increased risk of venous thromboembolism (VTE), but there is great variation among reported incidence rates. Most previous studies have focused on hospitalized patients with COVID-19, and only a few reports ... ...

Abstract	Introduction: COVID-19 is associated with an increased risk of venous thromboembolism (VTE), but there is great variation among reported incidence rates. Most previous studies have focused on hospitalized patients with COVID-19, and only a few reports are from population-based registries. Methods: We studied the 90-day incidence of VTE, associated risk factors and all-cause mortality in hospitalized and nonhospitalized patients with COVID-19 in a nationwide cohort. Data on hospitalizations and outpatient visits were extracted from two national registries with mandatory reporting linked by a unique national identification number carried by all Norwegian residents. We performed Cox proportional hazards regression to determine risk factors for VTE after infection with SARS-CoV-2. Results: Our study included 30,495 patients with positive SARS-CoV-2 polymerase chain reaction with a mean (SD) age of 41.9 (17.3) years, and 53% were males. Only 2081 (6.8%) were hospitalized. The 90-day incidence of VTE was 0.3% (95% CI: 0.21-0.33) overall and 2.9% (95% CI: 2.3-3.7) in hospitalized patients. Age (hazard ratio [HR] 1.28 per decade, 95% CI: 1.11-1.48, p < 0.05), history of previous VTE (HR 4.69, 95% CI: 2.34-9.40, p < 0.05), and hospitalization for COVID-19 (HR 23.83, 95% CI: 13.48-42.13, p < 0.05) were associated with risk of VTE. Conclusions: The 90-day incidence of VTE in hospitalized and nonhospitalized patients with COVID-19 was in the lower end compared with previous reports, with considerably higher rates in hospitalized than nonhospitalized patients. Risk factors for VTE were consistent with previously reported studies.
MeSH term(s)	Male ; Humans ; Adult ; Female ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/etiology ; COVID-19/complications ; COVID-19/epidemiology ; Incidence ; SARS-CoV-2 ; Anticoagulants ; Risk Factors
Chemical Substances	Anticoagulants
Language	English
Publishing date	2023-07-30
Publishing country	England
Document type	Journal Article
ZDB-ID	96274-0
ISSN	1365-2796 ; 0954-6820
ISSN (online)	1365-2796
ISSN	0954-6820
DOI	10.1111/joim.13706
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.44: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A man in his 70s with neurological symptoms and progressive pain during cancer therapy.

Tholin, Birgitte / Köster, Anne Katharina / Standal, Per Arne

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

2020 Volume 140, Issue 2

Abstract: Background: Bing-Neel syndrome is a rare neurological manifestation of Waldenström's macroglobulinaemia that can occur both before and after the diagnosis is set.: Case presentation: A man in his seventies with Waldenström's macroglobulinaemia under ... ...

Title translation	En mann i 70-årene med nevrologiske symptomer og progredierende smerter under kreftbehandling.
Abstract	Background: Bing-Neel syndrome is a rare neurological manifestation of Waldenström's macroglobulinaemia that can occur both before and after the diagnosis is set. Case presentation: A man in his seventies with Waldenström's macroglobulinaemia under treatment with ibrutinib contacted the outpatient clinic due to bilateral pain distal to the knees. We initially suspected it was a side effect of ibrutinib and discontinued the drug. A few days later, he returned with reduced general condition, fever, shivers and a limping gait, and was hospitalised. Clinical examination revealed only pulmonary crackles. With stable low IgM, CRP > 200 mg/L and fever we suspected a serious infection and started broad-spectrum antibiotic treatment. Microbiological tests were negative, and he developed no focal symptoms of infection, but the pain increased. The symptoms had commenced with paraesthesias, and neurological examination revealed ataxia, intentional tremor, decreased sensation distal to the knees and dysdiadochokinesia. Waldenström's macroglobulinaemia was present in the central nervous system, consistent with Bing-Neel syndrome. Brain MRI illustrated pathologically thickened and enhanced meninges and thickened, wavy cauda equine roots. Lumbar puncture showed monoclonal B-cells consistent with lymphoplasmacytic lymphoma. Two weeks after admission IgM had increased from 3.21 g/L to 17.2 g/L. We restarted ibrutinib at a higher dosage, and shortly after his neurological symptoms regressed and IgM normalised. Interpretation: The literature consists mainly of retrospective case reports, and there is no true consensus regarding diagnostic criteria or guidelines for treatment. We suspect Bing-Neel syndrome might be underdiagnosed and consider it important to bring awareness of the disease to clinicians.
MeSH term(s)	Aged ; Animals ; Horses ; Humans ; Magnetic Resonance Imaging ; Male ; Pain/chemically induced ; Pain/drug therapy ; Pyrazoles ; Retrospective Studies ; Waldenstrom Macroglobulinemia/diagnosis ; Waldenstrom Macroglobulinemia/drug therapy
Chemical Substances	Pyrazoles
Language	Norwegian
Publishing date	2020-01-20
Publishing country	Norway
Document type	Journal Article
ZDB-ID	603504-8
ISSN	0807-7096 ; 0029-2001
ISSN (online)	0807-7096
ISSN	0029-2001
DOI	10.4045/tidsskr.19.0303
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 422: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 546: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cognitive function in non-hospitalized patients 8-13 months after acute COVID-19 infection: A cohort study in Norway.

Stavem, Knut / Einvik, Gunnar / Tholin, Birgitte / Ghanima, Waleed / Hessen, Erik / Lundqvist, Christofer

PloS one

2022 Volume 17, Issue 8, Page(s) e0273352

Abstract: Studies have reported reduced cognitive function following COVID-19 illness, mostly from hospital settings with short follow-up times. This study recruited non-hospitalized COVID-19 patients from a general population to study prevalence of late cognitive ...

Abstract	Studies have reported reduced cognitive function following COVID-19 illness, mostly from hospital settings with short follow-up times. This study recruited non-hospitalized COVID-19 patients from a general population to study prevalence of late cognitive impairment and associations with initial symptoms. We invited patients with PCR-confirmed COVID-19. A postal questionnaire addressed basic demographics, initial COVID-19 symptoms and co-morbidity about 4 months after diagnosis. About 7 months later, we conducted cognitive tests using the Cambridge Neuropsychological Test Automated Battery, comprising four tests for short-term memory, attention and executive function. We present descriptive statistics using z-scores relative to UK population norms and defined impairment as z-score <-1.5. We used multivariable logistic regression with impairment as outcome. Continuous domain scores were analysed by multiple linear regression. Of the initial 458 participants; 305 were invited, and 234 (77%) completed cognitive testing. At median 11 (range 8-13) months after PCR positivity, cognitive scores for short term memory, visuospatial processing, learning and attention were lower than norms (p≤0.001). In each domain, 4-14% were cognitively impaired; 68/232 (29%) were impaired in ≥ 1 of 4 tests. There was no association between initial symptom severity and impairment. Multivariable linear regression showed association between spatial working memory and initial symptom load (6-9 symptoms vs. 0-5, coef. 4.26, 95% CI: 0.65; 7.86). No other dimension scores were associated with symptom load. At median 11 months after out-of-hospital SARS-Cov-2 infection, minor cognitive impairment was seen with little association between COVID-19 symptom severity and outcome.
MeSH term(s)	COVID-19/complications ; COVID-19/epidemiology ; Cognition ; Cognitive Dysfunction/epidemiology ; Cohort Studies ; Humans ; Neuropsychological Tests ; SARS-CoV-2
Language	English
Publishing date	2022-08-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0273352
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cognitive function in non-hospitalized patients 8-13 months after acute COVID-19 infection

Knut Stavem / Gunnar Einvik / Birgitte Tholin / Waleed Ghanima / Erik Hessen / Christofer Lundqvist

PLoS ONE, Vol 17, Iss 8, p e

A cohort study in Norway.

2022 Volume 0273352

Abstract	Studies have reported reduced cognitive function following COVID-19 illness, mostly from hospital settings with short follow-up times. This study recruited non-hospitalized COVID-19 patients from a general population to study prevalence of late cognitive impairment and associations with initial symptoms. We invited patients with PCR-confirmed COVID-19. A postal questionnaire addressed basic demographics, initial COVID-19 symptoms and co-morbidity about 4 months after diagnosis. About 7 months later, we conducted cognitive tests using the Cambridge Neuropsychological Test Automated Battery, comprising four tests for short-term memory, attention and executive function. We present descriptive statistics using z-scores relative to UK population norms and defined impairment as z-score <-1.5. We used multivariable logistic regression with impairment as outcome. Continuous domain scores were analysed by multiple linear regression. Of the initial 458 participants; 305 were invited, and 234 (77%) completed cognitive testing. At median 11 (range 8-13) months after PCR positivity, cognitive scores for short term memory, visuospatial processing, learning and attention were lower than norms (p≤0.001). In each domain, 4-14% were cognitively impaired; 68/232 (29%) were impaired in ≥ 1 of 4 tests. There was no association between initial symptom severity and impairment. Multivariable linear regression showed association between spatial working memory and initial symptom load (6-9 symptoms vs. 0-5, coef. 4.26, 95% CI: 0.65; 7.86). No other dimension scores were associated with symptom load. At median 11 months after out-of-hospital SARS-Cov-2 infection, minor cognitive impairment was seen with little association between COVID-19 symptom severity and outcome.
Keywords	Medicine ; R ; Science ; Q
Subject code	150 ; 616
Language	English
Publishing date	2022-01-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.

Tholin, Birgitte / Hauge, Marit Teigen / Aukrust, Pål / Fehrle, Lutz / Tvedt, Tor Henrik

Journal of medical case reports

2020 Volume 14, Issue 1, Page(s) 187

Abstract: Background: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated thrombotic ... ...

Abstract	Background: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement. Case presentation: In this case report we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023 μg/L, but also elevated C-reactive protein 334 mg/L and lactate dehydrogenase 1074 U/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off the respirator 11 days later. Conclusion: COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient's case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials.
MeSH term(s)	Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Betacoronavirus/isolation & purification ; C-Reactive Protein/analysis ; COVID-19 ; Coronavirus Infections/blood ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/therapy ; Ferritins/blood ; Humans ; Inflammation/blood ; Interleukin-6/analysis ; Interleukin-6/antagonists & inhibitors ; Lymphohistiocytosis, Hemophagocytic/etiology ; Male ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/therapy ; Respiration, Artificial/methods ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Interleukin-6 ; C-Reactive Protein (9007-41-4) ; Ferritins (9007-73-2) ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-10-15
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2269805-X
ISSN	1752-1947 ; 1752-1947
ISSN (online)	1752-1947
ISSN	1752-1947
DOI	10.1186/s13256-020-02503-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis.

Tholin, Birgitte / Ghanima, Waleed / Einvik, Gunnar / Aarli, Bernt / Brønstad, Eivind / Skjønsberg, Ole H / Stavem, Knut

British journal of haematology

2021 Volume 194, Issue 3, Page(s) 542–546

Abstract: Infection with coronavirus disease-2019 (COVID-19) may predispose for venous thromboembolism (VTE). There is wide variation in reported incidence rates of VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence of thrombotic complications ... ...

Abstract	Infection with coronavirus disease-2019 (COVID-19) may predispose for venous thromboembolism (VTE). There is wide variation in reported incidence rates of VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence of thrombotic complications in COVID-19 is uncertain. Here we present data on the incidence of VTE in both hospitalised and non-hospitalised patients from two ongoing prospective cohort studies. The incidence of VTE after diagnosis of COVID-19 was 3·9% [95% confidence interval (CI): 2·1-7·2] during hospitalisation, 0·9% (95% CI: 0·2-3·1) in the three months after discharge and 0·2% (95% CI: 0·00-1·25) in non-hospitalised patients, suggesting an incidence rate at the lower end of that in previous reports.
MeSH term(s)	Adult ; Aged ; Anticoagulants/therapeutic use ; COVID-19/complications ; COVID-19/diagnosis ; Female ; Heparin, Low-Molecular-Weight/therapeutic use ; Hospitalization ; Humans ; Incidence ; Male ; Middle Aged ; Prospective Studies ; Risk Factors ; SARS-CoV-2/isolation & purification ; Thrombosis/drug therapy ; Thrombosis/etiology ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/etiology
Chemical Substances	Anticoagulants ; Heparin, Low-Molecular-Weight
Language	English
Publishing date	2021-05-24
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.17522
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab

Birgitte Tholin / Marit Teigen Hauge / Pål Aukrust / Lutz Fehrle / Tor Henrik Tvedt

Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-

a case report

2020 Volume 5

Abstract: Abstract Background The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated ... ...

Abstract	Abstract Background The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement. Case presentation In this case report we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023 μg/L, but also elevated C-reactive protein 334 mg/L and lactate dehydrogenase 1074 U/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off the respirator 11 days later. Conclusion COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient’s case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials.
Keywords	COVID-19 ; HLH ; Hemophagocytic lymphohistiocytosis ; IL-6 ; Tocilizumab ; Case report ; Medicine ; R
Subject code	616
Language	English
Publishing date	2020-10-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis.

Tholin, Birgitte / Fiskvik, Hilde / Tveita, Anders / Tsykonova, Galina / Opperud, Helene / Busterud, Kari / Mpinganzima, Clarisse / Garabet, Lamya / Ahmed, Jamal / Stavem, Knut / Ghanima, Waleed

Thrombosis update

2022 Volume 6, Page(s) 100096

Abstract: Introduction: The incidence of thromboembolism during COVID-19 and the use of thromboprophylaxis vary greatly between studies. Only a few studies have investigated the rate of thromboembolism post-discharge. This study determined the 90-day incidence of ...

Abstract	Introduction: The incidence of thromboembolism during COVID-19 and the use of thromboprophylaxis vary greatly between studies. Only a few studies have investigated the rate of thromboembolism post-discharge. This study determined the 90-day incidence of venous and arterial thromboembolic complications, risk factors for venous thromboembolic events and characterized the use of thromboprophylaxis during and after hospitalization. Materials and methods: We retrospectively reviewed medical records for adult patients hospitalized for >24 h for COVID-19 before May 15, 2020, in ten Norwegian hospitals. We extracted data on demographics, thromboembolic complications, thromboembolic risk factors, and the use of thromboprophylaxis. Cox proportional hazards regression was used to determine risk factors for VTE. Results: 550 patients were included. The 90-day incidence of arterial and venous thromboembolism in hospitalized patients was 6.9% (95% CI: 5.1-9.3) overall and 13.8% in the ICU. Male sex (hazard ratio (HR) 7.44, 95% CI 1.73-32.02, Conclusions: The 90-day incidence of thromboembolism in COVID-19 patients was 7%, but <1% after discharge. Risk factors were male sex and previous VTE. Most patients received thromboprophylaxis during hospitalization, but only <10% after discharge.
Language	English
Publishing date	2022-01-03
Publishing country	England
Document type	Journal Article
ISSN	2666-5727
ISSN (online)	2666-5727
DOI	10.1016/j.tru.2021.100096
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report

Tholin, Birgitte / Hauge, Marit Teigen / Aukrust, Pål / Fehrle, Lutz / Tvedt, Tor Henrik

J Med Case Rep

Abstract: BACKGROUND: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated thrombotic ... ...

Abstract	BACKGROUND: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barré syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement. CASE PRESENTATION: In this case report we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023 µg/L, but also elevated C-reactive protein 334 mg/L and lactate dehydrogenase 1074 U/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off the respirator 11 days later. CONCLUSION: COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient's case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #863354
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial.

Kåsine, Trine / Dyrhol-Riise, Anne Ma / Barratt-Due, Andreas / Kildal, Anders Benjamin / Olsen, Inge Christoffer / Nezvalova-Henriksen, Katerina / Lund-Johansen, Fridtjof / Hoel, Hedda / Holten, Aleksander Rygh / Tveita, Anders / Mathiessen, Alexander / Haugli, Mette / Eiken, Ragnhild / Berg, Åse / Johannessen, Asgeir / Heggelund, Lars / Dahl, Tuva Børresdatter / Halvorsen, Bente / Mielnik, Pawel /

Journal of internal medicine

2021 Volume 291, Issue 2, Page(s) 241–243

MeSH term(s)	COVID-19/diagnosis ; COVID-19/immunology ; Humans ; Leukocyte Count ; Neutrophils/cytology ; Retrospective Studies ; SARS-CoV-2
Language	English
Publishing date	2021-10-03
Publishing country	England
Document type	Letter
ZDB-ID	96274-0
ISSN	1365-2796 ; 0954-6820
ISSN (online)	1365-2796
ISSN	0954-6820
DOI	10.1111/joim.13377
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.44: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito